Expanding horizons: lung transplantation for non-IPF interstitial lung diseases.
Langerhans cell histiocytosis X
Lung transplantation
Non-IPF ILD
Pleura parenchymal fibroelastosis
Silicosis
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
received:
09
08
2024
accepted:
19
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
2
10
2024
Statut:
epublish
Résumé
Interstitial lung diseases (ILDs) are diverse pulmonary disorders marked by diffuse lung inflammation and fibrosis. The variability in characteristics and treatment approaches complicates diagnosis and management. In advanced cases requiring transplantation, determining indications and selecting suitable candidates presents additional challenges. Of all patients with non-IPF ILD between December 2016 to December 2022 were analyzed retrospectively. Patients were categorized into two groups: transplanted patients and deceased patients on the waiting list. Clinical data and survival outcomes were compared between groups. Of the 43 patients, 20 underwent lung transplantation while 23 died awaiting transplantation. Waiting list mortality was 53.4%, with median waiting times similar between groups (3 months for transplant patients and 6 months for those on the waiting list). There were no significant differences between groups in age, gender, height, BMI, 6-minute walk test (6MWT), or forced vital capacity (FVC). The prevalence of pulmonary hypertension (PH) was 76.7% in right heart catheterizations, similar in both groups. One single and 19 bilateral lung transplants were performed. Overall, 13 of the 20 patients survived to discharge from the hospital. One-year mortality was 7/20 (35%). The median follow-up was 34 months, with a 1-year conditional survival of 90.9% at 3 years and 70.7% at 5 years. This study underscores the importance of further research into non-IPF ILDs. Lung transplantation remains a viable option that can significantly enhance both the quality and longevity of life for patients with advanced ILD.
Identifiants
pubmed: 39358764
doi: 10.1186/s12890-024-03291-4
pii: 10.1186/s12890-024-03291-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
482Informations de copyright
© 2024. The Author(s).
Références
Chizinga M, Machuca TN, Shahmohammadi A, et al. Lung transplantation for acute exacerbation of interstitial lung disease. Thorax. 2022;77(4):364–9.
doi: 10.1136/thoraxjnl-2020-215681
pubmed: 34226204
Zibrak JD, Price D. Interstitial lung disease: raising the index of suspicion in primary care. NPJ Prim Care Respir Med. 2014;24:14054.
doi: 10.1038/npjpcrm.2014.54
pubmed: 25208940
Kapnadak SG, Raghu G. Lung transplantation for interstitial lung disease. Eur Respir Rev. 2021;30(161):210017.
doi: 10.1183/16000617.0017-2021
pubmed: 34348979
pmcid: 9488499
Kern RM, Singer JP, Koth L, et al. Lung transplantation for hypersensitivity pneumonitis. Chest. 2015;147(6):1558–65.
doi: 10.1378/chest.14-1543
pubmed: 25412059
Dauriat G, Mal H, Thabut G, et al. Lung transplantation for pulmonary langerhans’ cell histiocytosis: a multicenter analysis. Transplantation. 2006;81(5):746–50.
doi: 10.1097/01.tp.0000200304.64613.af
pubmed: 16534477
De Meester J, Smits JM, Persijn GG, Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transpl. 2001;20(5):518–24.
doi: 10.1016/S1053-2498(01)00241-8
Kourliouros A, Hogg R, Mehew J, et al. Patient outcomes from time of listing for lung transplantation in the UK: are there disease-specific differences? Thorax. 2019;74(1):60–8.
doi: 10.1136/thoraxjnl-2018-211731
pubmed: 30282722
Iribarne A, Russo MJ, Davies RR, et al. Despite decreased wait-list times for lung transplantation, lung allocation scores continue to increase. Chest. 2009;135(4):923–8.
doi: 10.1378/chest.08-2052
pubmed: 19017874
Valapour M, Lehr CJ, Schladt DP, et al. Am J Transpl. 2024;24(2S1):S394–456. OPTN/SRTR 2022 Annual Data Report: Lung.
Stącel T, Nęcki M, Antończyk R, et al. Effectiveness of lung transplantation in patients with interstitial Lung diseases. Transpl Proc. 2020;52(7):2143–8.
doi: 10.1016/j.transproceed.2020.03.050
Bode H, Verleden SE, Wuyts WA, et al. Outcome of lung transplantation in non-idiopathic pulmonary fibrosis interstitial lung disease. Clin Transpl. 2019;33(10):e13661.
doi: 10.1111/ctr.13661
Kacprzak A, Tomkowski W, Szturmowicz M. Pulmonary hypertension in the course of interstitial lung Diseases-A Personalised Approach is needed to identify a Dominant cause and provide an effective therapy. Diagnostics (Basel). 2023;13(14):2354.
doi: 10.3390/diagnostics13142354
pubmed: 37510098
Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled Treprostinil in Pulmonary Hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325–34.
doi: 10.1056/NEJMoa2008470
pubmed: 33440084
Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620–8.
doi: 10.1056/NEJMoa1002110
pubmed: 20484178
Hoetzenecker K, Benazzo A, Stork T, et al. Vienna Lung Transplant Group. Bilateral lung transplantation on intraoperative extracorporeal membrane oxygenator: an observational study. J Thorac Cardiovasc Surg. 2020;160(1):320–7.
doi: 10.1016/j.jtcvs.2019.10.155
pubmed: 31932054
Erkılınç A, Vayvada M. The use of intraoperative extracorporeal membrane oxygenation in lung transplantation: initial institutional experience. Braz J Cardiovasc Surg. 2023;38(1):88–95.
doi: 10.21470/1678-9741-2021-0182
pubmed: 35657305
pmcid: 10010717
Perin FA, Altmayer S, Nascimento DZ, et al. Long-term survival following unilateral lung transplantation for end-stage silicosis relative to idiopathic pulmonary fibrosis. J Bras Pneumol. 2022;48(2):e20210513.
doi: 10.36416/1806-3756/e20210513
pubmed: 35475868
pmcid: 9064634